Market capitalization | $110.00k |
Enterprise Value | $-6.16m |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | -1.93 |
P/S ratio (TTM) P/S ratio | 0.03 |
Revenue growth (TTM) Revenue growth | -64.44% |
Revenue (TTM) Revenue | $3.20m |
EBIT (operating result TTM) EBIT | $-9.31m |
Free Cash Flow (TTM) Free Cash Flow | $9.22m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
2 Analysts have issued a TRACON Pharmaceuticals, Inc. forecast:
2 Analysts have issued a TRACON Pharmaceuticals, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 3.20 3.20 |
64%
64%
|
|
Gross Profit | 3.19 3.19 |
65%
65%
|
|
EBITDA | -9.29 -9.29 |
42%
42%
|
EBIT (Operating Income) EBIT | -9.31 -9.31 |
42%
42%
|
Net Profit | 5.20 5.20 |
118%
118%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types; TRC205 created for the treatment of fibrotic diseases; and TRC102, a small molecule that is in clinical development made for lung cancer and glioblastoma. The company was founded in October 2004 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Craig Jalbert |
Employees | 17 |
Founded | 2004 |
Website | www.traconpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.